'A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and there were no plans to pause this work to conserve cash.
Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce'
#Immunotherapy #Immunology #CARTcells
https://www.fiercebiotech.com/biotech/caribou-cuts-nk-cell-therapy-program-lays-12-staff-fund-car-t-priorities